View all research projects
Research project

Huneke (Baldwin) - MRC CRTF - Investigating the mechanisms of placebo anxiolysis - Jan 19

Staff

Lead researcher

Dr Nathan Huneke MBChB MRes MRCPsych

NIHR Academic Clinical Lecturer

Research interests

  • Experimental medicine
  • Neuroimaging
  • Placebo and nocebo effects
Connect with Nathan

Email: [email protected]

Other researchers

Professor Matthew Garner PhD

Head of School

Research interests

  • Neuropsychological mechanisms and treatment targets in anxiety disorders. 
  • Psychopharmacology/experimental medicine (acute pharmacological challenge).
  • Psychophysiology (e.g. interoception, autonomic markers of emotion processing),
Connect with Matthew

Email: [email protected]

Professor David Baldwin

Professor in Psychiatry
Connect with David

Email: [email protected]

Research outputs

Placebo effects are small on average in the 7.5% CO2 inhalational model of generalized anxiety
Nathan T.M. Huneke, Cosmina Cross, Harry A. Fagan, Laura Molteni, Naomi Phillips, Matthew Garner & David S. Baldwin, 2024, International Journal of Neuropsychopharmacology, 27(4)
DOI: 10.1093/ijnp/pyae019
Type: article
Placebo effects are small on average in the 7.5% CO2 inhalational model of generalised anxiety
Nathan T.M. Huneke, Cosmina Cross, Harry A. Fagan, Laura Molteni, Naomi Phillips, Matthew Garner & David S. Baldwin, 2024, International Journal of Neuropsychopharmacology, 27(4)
DOI: 10.1093/ijnp/pyae019
Type: article
Exploring the psychoneurobiology of the placebo response in gambling, depressive, and anxiety disorders
Nathan Huneke, 2023
Type: thesis
A novel procedure to investigate social anxiety using videoconferencing software:
Nathan Huneke, Hannah Rowlett, Joshua Hyde, Alexander McEwan, Louise Maryan, David S. Baldwin & Matthew Garner, 2022, Journal of Psychiatric Research, 316
DOI: 10.1016/j.psychres.2022.114770
Type: article
Is superiority to placebo the most appropriate measure of efficacy in trials of novel psychotropic medications?
Nathan Huneke, 2022, European Neuropsychopharmacology, 62, 7-9
DOI: 10.1016/j.euroneuro.2022.06.003
Type: article